A prospective, non-interventional study (NIS) with trastuzumab deruxtecan for patients with HER2-low expressing unresectable and/or metastatic breast cancer accompanied by a disease registry of patients treated with conventional chemotherapy (DESTINY Breast Respond HER2-low Europe)

ENCePP Code of conduct

N/A

Data sources

• Data sources (types):
  Other
• Data sources (types), other:
  As this is a non-interventional study, only data on clinical routine practice will be documented. To facilitate accurate recording of data, patients can optionally fill in a memory aid to note important details.

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  Unknown